- Home
- BZUN vs IPHA Comparison
BZUN vs IPHA Comparison
Compare BZUN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- IPHA
- Stock Information
- Founded
- BZUN 2007
- IPHA 1999
- Country
- BZUN China
- IPHA France
- Employees
- BZUN N/A
- IPHA N/A
- Industry
- BZUN Catalog/Specialty Distribution
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- IPHA Health Care
- Exchange
- BZUN Nasdaq
- IPHA Nasdaq
- Market Cap
- BZUN 275.9M
- IPHA 160.1M
- IPO Year
- BZUN N/A
- IPHA 2019
- Fundamental
- Price
- BZUN $4.58
- IPHA $2.05
- Analyst Decision
- BZUN Strong Buy
- IPHA Strong Buy
- Analyst Count
- BZUN 1
- IPHA 1
- Target Price
- BZUN $4.20
- IPHA $11.00
- AVG Volume (30 Days)
- BZUN 735.7K
- IPHA 14.6K
- Earning Date
- BZUN 08-28-2025
- IPHA 09-17-2025
- Dividend Yield
- BZUN N/A
- IPHA N/A
- EPS Growth
- BZUN N/A
- IPHA N/A
- EPS
- BZUN N/A
- IPHA N/A
- Revenue
- BZUN $1,349,630,922.00
- IPHA $14,839,695.00
- Revenue This Year
- BZUN $5.27
- IPHA $350.96
- Revenue Next Year
- BZUN $3.46
- IPHA $32.92
- P/E Ratio
- BZUN N/A
- IPHA N/A
- Revenue Growth
- BZUN 7.73
- IPHA N/A
- 52 Week Low
- BZUN $2.12
- IPHA $1.29
- 52 Week High
- BZUN $4.88
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- BZUN 70.87
- IPHA 46.87
- Support Level
- BZUN $4.32
- IPHA $1.93
- Resistance Level
- BZUN $4.88
- IPHA $2.19
- Average True Range (ATR)
- BZUN 0.36
- IPHA 0.11
- MACD
- BZUN 0.09
- IPHA -0.01
- Stochastic Oscillator
- BZUN 86.11
- IPHA 49.66
About BZUN Baozun Inc.
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.